AERSUN

AERSUN, incubated from Hubei Zhongchuang Medical Supplies Co., Ltd., was established as an independent company in 2023. As a professional R&D and manufacturing enterprise in the field of tissue repair and reconstruction, the company focuses on the development, production, and sales of high-end implantable medical device products. AERSUN not only has deep cooperation with Wuhan University of Technology but also has established long-term partnerships with clinical medicine experts in China. It closely aligns with clinical needs, promotes the integration of medicine and engineering, and connects the industry chain of research, production, academia, and medicine. AERSUN's small-caliber artificial blood vessels utilize proprietary technology to address clinical pain points in product development. Currently, within the Zhongchuang Health Industrial Park located in Jiangxia District, Wuhan, the company has built a Class 10,000 GMP workshop, advanced laboratories, and other facilities, forming capabilities in R&D, production, and testing, while advancing the clinical trials of small-caliber artificial blood vessels.